Browsing Category
Pharma Industry News
4720 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Rznomics gets FDA RMAT status for RZ-001, but can one liver cancer signal carry a platform story?
RNA editing has a regulatory opening in liver cancer. Rznomics now must prove RZ-001 can turn FDA momentum into durable clinical value.
Why complement pathway competition in renal disease is intensifying around oral C5aR therapies
InflaRx N.V. is expanding izicopan across renal diseases as complement therapy competition intensifies. Discover what this means for nephrology markets.
Why regulators are closely watching BIOX-101 in spontaneous intracerebral hemorrhage
Why are regulators closely watching BIOX-101 in hemorrhagic stroke? Explore how Bioxodes is targeting accelerated approval pathways.
From metabolism to genetics: Can ARO-PNPLA3 change the MASH playbook
Can ARO-PNPLA3 reshape MASH drug development? Discover how Madrigal Pharmaceuticals, Inc. is expanding into precision therapies.
Why BTK inhibitor resistance is becoming a growth driver for Cellectar Biosciences, Inc. (NASDAQ: CLRB)
Can Cellectar Biosciences, Inc. turn BTK inhibitor resistance into an opportunity? Explore what iopofosine I 131 means for WM strategy.
Catalyst Pharmaceuticals (CPRX) agrees $4.1bn buyout as Angelini Pharma plans to enter US rare disease market
Angelini Pharma will pay $4.1 billion for Catalyst Pharmaceuticals at $31.50 a share, but CPRX closed at $31.10. The premium sits in the strategy, not the price.
Harbour BioMed FDA IND clearance puts HBM7004 into the clinical spotlight as bispecific oncology race intensifies
Harbour BioMed has FDA clearance, but HBM7004 must now prove whether its B7H4xCD3 design can translate platform science into clinical value.
Can in vivo CAR T therapies expand access beyond specialized treatment centers
Explore how CPTx’s in vivo CAR T strategy could lower costs, simplify delivery, and expand access beyond specialized cancer treatment centers.
A durability breakthrough or early signal? What pelareorep means for resistant colorectal cancer
Can durability redefine MSS colorectal cancer? Discover how Oncolytics Biotech, Inc.’s pelareorep data could shift treatment strategy and market dynamics.
Biomarker promise or clinical reality: What ASPENOVA will prove or disprove
Can ASPENOVA validate biomarker-driven ovarian cancer therapy? Discover what Zentalis Pharmaceuticals, Inc.’s strategy means for the industry.